Metabolomic Mapping of Atypical Antipsychotic Effects in Schizophrenia

Kaddurah-Daouk, R, McEvoy, J, Baillie, R A, Lee, D, Yao, J K, Doraiswamy, P M, Krishnan, K R R·2007·Molecular Psychiatry
DOI 10.1038/sj.mp.4002000

Cited by (261)

Items 201–261 of 261

  1. Multi-omics reveal critical roles of phosphatidylcholine and sphingomyelin in antipsychotic efficacy for schizophrenia
    Junyuan Sun, Zhe Lu, Zhewei Kang, Yuyanan Zhang, Yaoyao Sun, Guorui Zhao, Qijing Bo, Wenqiang Li, Zhenghui Yi, Binbin Chen et al. · 2025 · Signal Transduction and Targeted Therapy
  2. Schizophrenia and cardiometabolic disorders
    Grigory V. Rukavishnikov, Evgeny Dmitrievich Kasyanov, Tatyana Vladimirovna Zhilyaeva, Galina Elevna Mazo · 2021 · S S Korsakov Journal of Neurology and Psychiatry
  3. Anthranilic Acid–G-Protein Coupled Receptor109A–Cytosolic Phospholipase A2–Myelin–Cognition Cascade: A New Target for the Treatment/Prevention of Cognitive Impairment in Schizophrenia, Dementia, and Aging
    Gregory F. Oxenkrug · 2024 · International Journal of Molecular Sciences
  4. Identifying serum lipidomic signatures related to prognosis in first-episode schizophrenia
    Mengyi Luo, Suzhen Zhang, Jingxin Xue, Tianhao Gao, Xuan Li, Zhaolin Zhai, Chang Lu, Yuke Dong, Kaiming Zhuo, Qiong Xiang et al. · 2025 · BMC Psychiatry
  5. Metabolomics of Psychotic Disorders
    Tammie T Money Chad A Bousman · 2013 · Journal of Postgenomics Drug & Biomarker Development
  6. Formidable Challenges in the Search for Biomarkers of Psychiatric Disorders
    Chad Bousman, Ian Everall · 2011 · Journal of Postgenomics Drug & Biomarker Development
  7. Plasma linoelaidyl carnitine levels positively correlated with symptom improvement in olanzapine-treated first-episode drug-naïve schizophrenia
    Xuan Wang, Meihong Xiu, Keqiang Wang, Xiuru Su, Xirong Li, Fengchun Wu · 2022 · Metabolomics
  8. Plasma and Serum LC-MS Lipidomic Fingerprints of Bipolar Disorder and Schizophrenia
    Marija M. Takić, Vesna Božić Jovanović, Suzana Marković, Zoran P. Miladinović, Milka B. Jadranin, Gordana Krstić, Čedo Miljević, Vele Tešević, Boris Mandić · 2025 · International Journal of Molecular Sciences
  9. Biomarker discovery in neurological diseases: a metabolomic approach
    Afaf K El-Ansary · 2009 · Open Access Journal of Clinical Trials
  10. Specialized Information Processing Deficits and Distinct Metabolomic Profiles Following TM-Domain Disruption of Nrg1
    Colm M. P. O’Tuathaigh, Naina Mathur, Matthew J. O’Callaghan, Lynsey MacIntyre, Richard Paul Harvey, Donna Lai, John L. Waddington, Ben S. Pickard, David George Watson, Paula M. Moran · 2016 · Schizophrenia Bulletin
  11. Big Data in Severe Mental Illness: the Role of Electronic Monitoring Tools and Metabolomics
    Hema Sekhar Reddy Rajula, Mirko Manchia, Bernardo Carpiniello, Vassilios Fanos · 2020 · Personalized Medicine
  12. Metabolomics of Schizophrenia
    Dan Rujescu, Ina Giegling · 2016 · Elsevier eBooks
  13. Hunting for Peripheral Biomarkers to Support Drug Development in Psychiatry
    E. Domenici, P. Muglia, E. Merlo-Pich · 2008 · Springer eBooks
  14. Precautions for study design and data interpretation of clinical metabolomics
    Jinping Zheng, Kaiqiang Wang, Yuefei Wang, Kefeng Li · 2022 · Proceedings of the National Academy of Sciences
  15. Pharmacometabolomics: General Applications of Metabolomics in Drug Development and Personalized Medicine
    Dung Thuy Tran, Amber Dahlin · 2023 · Springer eBooks
  16. Monitoring central nervous system tumour metabolism using cerebrospinal fluid
    Alison Whitby, Madhumita Dandapani · 2024 · Frontiers in Oncology
  17. Targeted and Non-Targeted Metabolomic Evaluation of Cerebrospinal Fluid in Early Phase Schizophrenia: A Pilot Study from the Hopkins First Episode Psychosis Project
    George Eugene Jaskiw, Mark E. Obrenovich, Curtis J. Donskey, Farren B. S. Briggs, Sun Sunnie Chung, Anastasiya I. Kalinina, Austin C. Bolomey, Lindsay N. Hayes, Kun Yang, Robert H. Yolken et al. · 2025 · Metabolites
  18. Profiling the Skeletal Muscle Proteome in Patients on Atypical Antipsychotics and Mood Stabilizers
    Kyle Jon Burghardt, Griffin Calme, Michael A. Caruso, Bradley H. Howlett, Elani Sanders, Zaher Msallaty, Abdullah Mallisho, Berhane Seyoum, Yue Andy Qi, Xiangmin Zhang et al. · 2022 · Brain Sciences
  19. Metabolomics mapping changed after olanzapine therapy in drug-naive schizophrenia patients—the significant impact of gene polymorphisms
    Bensu Karahalıl, Aylin Elkama, Mehmet Ak, Emirhan Nemutlu · 2022 · Toxicology Research
  20. Perspectives for an Integrated Biomarker Approach to Drug Discovery and Development
    Irina A. Antonijevic, Roman P. Artymyshyn, Carlos Forray, Sylvia A. Rabacchi, Kelli E. Smith, Chad J. Swanson, Joseph A. Tamm, Wiktor Mazin, Christophe Gerald · 2008 · Springer eBooks
  21. Molecular medicine: a path towards a personalized medicine
    Débora Marques de Miranda, Marcelo Henrique Mamede, Bruno Rezende Souza, Alexandre Guimarães de Almeida Barros, Luiz Alexandre Viana Magno, Antônio Alvim-Soares, Daniela Valadão Rosa, Célio José de Castro, Leandro Fernandes Malloy‐Diniz, Marcus V. Gomez et al. · 2012 · Brazilian Journal of Psychiatry
  22. Schizophrenia Host Vulnerability and Risk of Metabolic Disturbances During Treatment with Antipsychotics
    P.F. Buckley, Adriana E. Foster, Brian J. Miller · 2008 · FOCUS The Journal of Lifelong Learning in Psychiatry
  23. Biomarker Discovery in Major Psychiatric Disorders: Approaches, Limitations, and Future Directions
    A Bousman, Gursharan Chana, Tatro, Glatt, Ming T. Tsuang, Ian Everall · 2009
  24. Identification of Plasma Biomarkers in Untreated Schizophrenia Patients Using Untargeted Lipid Metabolomics
    Zhiqiang Wang, Yanyu Wang, Haonan Jiang, Long Chen, Xulai Zhang · 2025 · Neuropsychiatric Disease and Treatment
  25. Metabolic Plasticity in Schizophrenia: Clinical Rehabilitation Meets LC–MS Metabolomics and Neurofeedback
    Mateusz Trubalski, Renata Markiewicz, Agnieszka Markiewicz-Gospodarek, Grzegorz Kalisz, Bartosz Łoza, Sylwia Szymańczyk · 2025 · International Journal of Molecular Sciences
  26. Neurodevelopmental trajectories, polygenic risk, and lipometabolism in vulnerability and resilience to schizophrenia
    Jia Duan, Xiaohong Gong, Fay Y. Womer, Kaijin Sun, Lili Tang, Juan Liu, Junjie Zheng, Yue Zhu, Yanqing Tang, Xizhe Zhang et al. · 2023 · BMC Psychiatry
  27. Cognitive improvements linked to lysophosphatidylethanolamine after olanzapine treatment in drug-naïve first-episode schizophrenia
    Juanhua Li, Yuanguang Xu, Xin Wang, Caixing Liu, Zezhi Li, Meihong Xiu, Hongying Chen · 2024 · Metabolomics
  28. Comprehensive Metabolic Analysis for Understanding of Disease
    Christopher B. Newgard, Robert D. Stevens, Brett R. Wenner, Shawn C. Burgess, Olga Ilkayeva, Michael J. Muehlbauer, A. Dean Sherry, James Ralph Bain · 2010 · Elsevier eBooks
  29. Metabolomics Approaches in Toxicology
    Yvonne S. Lin, Laura M. Shireman, Savannah J. McFeely · 2017 · Elsevier eBooks
  30. Metabolomics in neuroscience and disease
    Caroline D. Rae · 2014
  31. Serum lipid metabolic characteristics and potential biomarkers in first-episode schizophrenia
    Suzhen Zhang, Mengyi Luo, Xinping Kuai, Xuan Li, Tianhao Gao, Yuke Dong, Chang Lu, Kaiming Zhuo, Qiong Xiang, Dengtang Liu · 2025 · BMC Psychiatry
  32. Endocannabinoids and polyunsaturated fatty acids in early schizophrenia: Changes under antipsychotics and association with the response to treatment
    Ameni Riahi, Rania Lansari, Mohamed Kacem Ben Fradj, W. Ben Flah, Khouloud Hkimi, B. Emna, Wahid Melki, Moncef Feki · 2026 · Prostaglandins Leukotrienes and Essential Fatty Acids
  33. Lipidomics, Mass Spectrometry, and Bioinformatics
    Jürgen Hartler, Harald C. Köfeler, Christopher J. O. Baker, Ravi Tharakan, Gerhard Thallinger · 2012 · Springer eBooks
  34. Quantifying Interactions Between Lipids and Surfaces
    Abhijeet Patra · 2016 · Springer theses
  35. Polarity gradient issues in differential centrifugation of complex lipid mixtures
    Varuzhan A. Sarkisyan, Yulia V. Frolova, Шипелин Владимир Александрович, Vera Mitrofanovna Kodentsova, Alla Alekseevna Kochetkova · 2019 · Proceedings of universities Applied chemistry and biotechnology
  36. Metabolomics in psychiatry
    Renee‐Marie Ragguett, Roger S. McIntyre · 2019 · Elsevier eBooks
  37. Lipidomics for Health and Disease
    2016 · Wiley eBooks
  38. Metabolic Signature of Antipsychotics used in the Treatment of Autism
    Nira Ben‐Jonathan · 2013
  39. Biological Methods for Metabolic Research
    Arancha Cebrián, Laura Menchén, Elsa Sánchez‐López, Juan Casado‐Vela, Santiago Díaz‐Moralli, Marta Cascante, Teresa Gómez del Pulgar, Juan Carlos Lacal · 2013 · Cambridge University Press eBooks
  40. ELEVATED SERUM SPHINGOMYELIN ASSOCIATES WITH REDUCED GRAY MATTER DENSITY: EVIDENCE FROM TWINS DISCORDANT FOR SCHIZOPHRENIA
    Matej Orešič, Tuulikki Seppänen‐Laakso, Sebastian Therman, Daqiang Sun, Jing Ping Tang, Ulla Mustonen, Theo G.M. van Erp, Marko Sysi‐Aho, Jaana Suvisaari, Leena Peltonen et al. · 2010 · Schizophrenia Research
  41. Blood-based Biomarkers for Personalised Medicine Applications in Schizophrenia
    Jakub Tomasik · 2014 · EUR Research Repository (Erasmus University Rotterdam)
  42. Schizophrenia: Blood-Serum-Plasma Metabolomics
    Simone Lista, Ina Giegling, Dan Rujescu · 2014 · Advances in biological psychiatry
  43. Metabolomics to Study Psychotic Disorders and Their Metabolic Comorbidities
    Matej Orešič · 2014 · Advances in biological psychiatry
  44. Avaliação dos perfis metabonomicos, proteomicos e metalomicos para o transtorno afetivo bipolar e seu tratamento com litio em amostras de soro sanguineo
    Alessandra Sussulini · 2010
  45. Comprehensive Metabolic Analysis for Understanding of Disease Mechanisms
    Christopher B. Newgard, Robert D. Stevens, Brett R. Wenner, Shawn C. Burgess, Olga Ilkayeva, Michael J. Muehlbauer, A. Dean Sherry, James Ralph Bain · 2009 · Elsevier eBooks
  46. The Role of Antipsychotic Medications in Metabolic Syndrome Amongst a Predisposed Population: Review of The Saudi Case
    Rashad Alsanosy · 2017 · Journal of Metabolic Syndrome
  47. Pharmacogenetics and personalized medicine
    Rocío Núñez‐Torres, Anna González‐Neira · 2021 · Elsevier eBooks
  48. Estudo translacional do receptor N-metil-d-aspartato em primeiro episódio psicótico e em modelos animais de psicose
    Camila Marcelino Loureiro · 2021
  49. Beyond Pharmacogenetics
    Roberto Canaparo · 2012 · InTech eBooks
  50. Faculty Opinions recommendation of Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics.
    James Steven Leeder, Andrea Gaedigk · 2011 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  51. Faculty Opinions recommendation of Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.
    Karen Wagner · 2009 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  52. Marcadores periféricos de metabolismo de membrana: caracterização de indivíduos com alto risco para psicose
    Alana C. Costa · 2023
  53. Metabolic pathway modulation by olanzapine: Multitarget approach for treating violent aggression in patients with schizophrenia
    Yan-Ning Song, Shuang Xia, Zhihong Sun, Yongchao Chen, Jiao Lu, Wen-Hua Wan, Hongwei Zhang, Xiao Hui Guo, Hua Guo, Shou-Feng Jia et al. · 2024 · World Journal of Psychiatry
  54. Altered Lipid Landscapes Provide a Molecular Perspective on Schizophrenia
    Robin Roychaudhuri · 2025 · Journal of Psychiatry and Brain Science
  55. Metabolomics in Alzheimer's disease
    Mohammed Zubair · 2013 · Research Explorer (The University of Manchester)
  56. Developing a rodent model for antipsychotic-induced metabolic adverse effects
    Silje Skrede · 2012 · NORA - Norwegian Open Research Archives
  57. Lysophosphatidylethanolamine correlated with cognitive improvements after treatment with olanzapine in drug-naïve first-episode schizophrenia: a prospective cohort study
    Lei Su, Meihong Xiu, Xiaoni Guan, Fan Wu · 2022 · Research Square
  58. Additional file 1 of Neurodevelopmental trajectories, polygenic risk, and lipometabolism in vulnerability and resilience to schizophrenia
    Jia Duan, Gong, Xiaohong, Fay Y. Womer, Kaijin Sun, Tang, Lili, Liu, Juan, Zheng, Junjie, Zhu, Yue, Tang, Yanqing, Zhang, Xizhe et al. · 2023 · Figshare
  59. Psychopharmacolipidomics: Understanding the Global Impact of Psychopharmacologic Treatments on Plasma Lipidomic Profiles
    Annika Weber, Sergi Papiol, Anna Tkachev, Fanny Senner, Daniela Reich‐Erkelenz, Alba Navarro‐Flores, Mojtaba Oraki Kohshour, Urs Heilbronner, M. Heilbronner, Monika Budde et al. · 2026 · medRxiv
  60. Caractérisation des perturbations métaboliques induites par les antipsychotiques dans un modèle murin : approches par la résonance magnétique
    Florent Auger · 2014
  61. Cell type-specific alterations in fatty acid metabolism in neuronal subpopulations of schizophrenia and construction of a diagnostic model
    Cui Zhao, Liang Zhang, Ping Yang, Li L, Weiqi Zeng, Weiqi Xie · 2026 · Frontiers in Psychiatry